August 13, 2020

The Niche

Knoepfler lab stem cell blog

advanced cell technology

3 min read

Advanced Cell Technology (ACT) is well into clinical trials for macular degeneration (the leading cause of blindness) using human embryonic stem cell (hESC)-based retinal pigmented epithelial cells (RPE). To date, the trials suggest the products are safe. Efficacy? We don’t know. I am cautiously hopeful, but it is frustrating to know that most clinical trials fail. Lest you think that ACT is a one trick pony, it is doing a bunch of other interesting stuff too including using induced pluripotent stem (iPS) cells. Over …Read More

3 min read

Today after years of following the company Advanced Cell Technology (ACT), I finally bought stock (ACTC) in it. Why? As a stem cell researcher myself working on human ES cells, iPS cells, and many other types of stem cells, I have been following ACT for years, but have never pulled the trigger to buy their stock….until now. They are conducting research on using human ES cell-based technology as treatments for blindness. They are also currently the only company with FDA approved clinical trials underway. At …Read More